Erratum: Targeting the NLRP3 inflammasome in inflammatory diseases
Open accessAbstract
This corrects the article DOI: 10.1038/nrd.2018.97.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
This response includes the recruitment of neutrophils and monocytes, which play crucial roles in tissue repair and healing processes.
“This response includes the recruitment of neutrophils and monocytes, which play crucial roles in tissue repair and healing processes.”
From Inflammation and aging: signaling pathways and intervention therapies (2023) · cites this paper as [278]
DAMPs from senescent, damaged, and dying cells trigger various cell death modalities, including necrosis, pyroptosis, necroptosis, PANoptosis, NETosis, and ferroptosis.
“In summary, DAMPs from senescent, damaged, and dying cells trigger various cell death modalities, including necrosis, pyroptosis, necroptosis, PANoptosis, NETosis, and ferroptosis (Fig. 4).”
From Inflammation and aging: signaling pathways and intervention therapies (2023) · cites this paper as [278]
DAMPs bind to specific receptors, initiating inflammation and orchestrating a coordinated response involving immune cells.
“DAMPs bind to specific receptors, initiating inflammation and orchestrating a coordinated response involving immune cells.”
From Inflammation and aging: signaling pathways and intervention therapies (2023) · cites this paper as [278]
When leukocytes fail to clear immunostimulatory molecules, inflammation persists, which further causes cancer and aging.
“When leukocytes fail to clear immunostimulatory molecules, inflammation persists, which further causes cancer and aging.”
From Inflammation and aging: signaling pathways and intervention therapies (2023) · cites this paper as [278]
Endogenous DAMPs can activate PRRs and non-PRR transmembrane proteins, resulting in massive inflammation, cellular senescence, diseases of the organs, and aging.
“Endogenous DAMPs can activate PRRs and non-PRR transmembrane proteins, resulting in massive inflammation, cellular senescence, diseases of the organs, and aging.277–279”
From Inflammation and aging: signaling pathways and intervention therapies (2023) · cites this paper as [278]
Cites
Targeting the NLRP3 inflammasome in inflammatory diseases
Mangan, M. S. J., Olhava, E. J., Roush, W. R., Seidel, H. M., Glick, G. D., & Latz, E. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2018.97 · Cited by 1,885 · see citing works
Self-citation
Flagged first, then by citations
Cited by
Sorted by citations
Inflammation and aging: signaling pathways and intervention therapies
Li, X., Li, C., Zhang, W., Wang, Y., Qian, P., & Huang, H. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01502-8 · Cited by 1,443 · see citing works
Xian, H., Watari, K., Sanchez-Lopez, E., Offenberger, J., Onyuru, J., Sampath, H., Ying, W., Hoffman, H. M., Shadel, G. S., & Karin, M. (2022) · Immunity · doi:10.1016/j.immuni.2022.06.007 · Cited by 850 · see citing works
The central role of inflammatory signaling in the pathogenesis of myelodysplastic syndromes
Sallman, D. A., & List, A. (2019) · Blood · doi:10.1182/blood-2018-10-844654 · Cited by 273 · see citing works
Therapeutic potential of MCC950, a specific inhibitor of NLRP3 inflammasome
Li, H., Guan, Y., Liang, B., Ding, P., Hou, X., Wei, W., & Ma, Y. (2022) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2022.175091 · Cited by 258 · see citing works
Pellegrini, C., Antonioli, L., Calderone, V., Colucci, R., Fornai, M., & Blandizzi, C. (2020) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2020.101806 · Cited by 174 · see citing works
Novel antiatherosclerotic therapies
Libby, P., & Everett, B. M. (2019) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.118.310958 · Cited by 145 · see citing works
Zhu, C., Li, H., Kong, X., Wang, Y., Sun, T., & Wang, F. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.819470 · Cited by 26 · see citing works
- Authors
- Mangan, M. S. J., Olhava, E. J., Roush, W. R., Seidel, H. M., Glick, G. D., & Latz, E.
- Venue
- Nature Reviews Drug Discovery
- Published
- 2018-08-17
- Volume
- 17
- Issue
- 9
- Pages
- 688-688
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W2947089396
- Cited by
- 465
- References
- 1
- Citations by year
- 2026: 49 · 2025: 64 · 2024: 83 · 2023: 77 · 2022: 74 · 2021: 40 · 2020: 56 · 2019: 19 · 2018: 3
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Reviews Drug Discovery (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Inflammasome and immune disorders
- Life Sciences › Immunology and Microbiology › Immunology › Immune Response and Inflammation
- Health Sciences › Medicine › Complementary and alternative medicine › Natural Compounds in Disease Treatment
- Keywords
- NLRP3 inflammasome, inflammatory diseases, inflammasome inhibitors, drug discovery
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
